Research ArticleArticle
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid
Manel Aouri, Catalina Barcelo, Béatrice Ternon, Matthias Cavassini, Alexia Anagnostopoulos, Sabine Yerly, Henry Hugues, Pietro Vernazza, Huldrych F. Günthard, Thierry Buclin, Amalio Telenti, Margalida Rotger, Laurent A. Decosterd and the Swiss HIV Cohort Study
Drug Metabolism and Disposition January 2016, 44 (1) 151-161; DOI: https://doi.org/10.1124/dmd.115.065839
Manel Aouri
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Catalina Barcelo
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Béatrice Ternon
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Matthias Cavassini
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Alexia Anagnostopoulos
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Sabine Yerly
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Henry Hugues
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Pietro Vernazza
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Huldrych F. Günthard
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Thierry Buclin
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Amalio Telenti
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Margalida Rotger
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Laurent A. Decosterd
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
Laboratory of Clinical Pharmacology, Service of Biomedicine (M.A., B.T., M.R., L.A.D.), Division of Clinical Pharmacology, Service of Biomedicine (M.A., C.B., T.B.), Service of Infectious Diseases (B.T., M.C.), Institute of Microbiology (A.T., M.R.), and Innovation and Development, Service of Biomedicine (H.H.), University Hospital and University of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland (A.A., H.F.G.); Institute of Medical Virology, University of Zurich, Zurich, Switzerland (H.F.G.); Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland (P.V.); Laboratory of Virology, University Hospital of Geneva, Geneva, Switzerland (S.Y.); and The J. Craig Venter Institute, La Jolla, California (A.T.)
![Loading Loading](https://dmd.aspetjournals.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Known and New In Vivo Phase I and II Efavirenz Metabolites
Manel Aouri, Catalina Barcelo, Béatrice Ternon, Matthias Cavassini, Alexia Anagnostopoulos, Sabine Yerly, Henry Hugues, Pietro Vernazza, Huldrych F. Günthard, Thierry Buclin, Amalio Telenti, Margalida Rotger, Laurent A. Decosterd and the Swiss HIV Cohort Study
Drug Metabolism and Disposition January 1, 2016, 44 (1) 151-161; DOI: https://doi.org/10.1124/dmd.115.065839
Research ArticleArticle
Known and New In Vivo Phase I and II Efavirenz Metabolites
Manel Aouri, Catalina Barcelo, Béatrice Ternon, Matthias Cavassini, Alexia Anagnostopoulos, Sabine Yerly, Henry Hugues, Pietro Vernazza, Huldrych F. Günthard, Thierry Buclin, Amalio Telenti, Margalida Rotger, Laurent A. Decosterd and the Swiss HIV Cohort Study
Drug Metabolism and Disposition January 1, 2016, 44 (1) 151-161; DOI: https://doi.org/10.1124/dmd.115.065839
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement